Endometrial stromal tumor

Summary

Endometrial stromal tumor (MONDO:0003311) is a cancer and 2 clinical trials. Top therapeutic interventions include vorinostat. A subtype of endometrium neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrial stromal tumor
Mondo ID	MONDO:0003311
EFO	EFO:1000920
MeSH	D036821
DOID	DOID:5166
SNOMED CT	446887007
UMLS	C0334695
MedGen	87280
Anatomy (UBERON)	UBERON:0002337
Is cancer (heuristic)	yes

Also known as: endometrial stroma neoplasm · endometrial stroma tumor · endometrial stroma tumour · endometrial stromal tumor (morphologic abnormality) · endometrial stromal tumour (morphologic abnormality) · neoplasm of endometrial stroma · tumor of endometrial stroma · tumour of endometrial stroma

Disease family

This is a subtype of endometrium neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › endometrial disorder › endometrium neoplasm › endometrial stromal tumor

Related subtypes (3): endometrial cancer, benign neoplasm of endometrium, fallopian tube endometrioid tumor

Subtypes (1): endometrioid stromal sarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03509207	PHASE2	TERMINATED	Vorinostat (SAHA) in Uterine Sarcoma
NCT02829437	Not specified	RECRUITING	Observational Study on Endometrial Stromal Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VORINOSTAT	4	1